scispace - formally typeset
H

Hong Duck Kim

Researcher at New York Medical College

Publications -  46
Citations -  1661

Hong Duck Kim is an academic researcher from New York Medical College. The author has contributed to research in topics: Adipogenesis & Adipocyte. The author has an hindex of 15, co-authored 40 publications receiving 1483 citations. Previous affiliations of Hong Duck Kim include University of Illinois at Chicago & University of Alabama at Birmingham.

Papers
More filters
Journal ArticleDOI

Role of toll-like receptor signalling in Aβ uptake and clearance

TL;DR: In this paper, the role of TLR4 in the amyloidogenesis in vivo, determined the amounts of cerebral Abeta in Alzheimer's disease mouse models with different genotypes of TLRs using three distinct methods.
Journal ArticleDOI

Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease

TL;DR: The first demonstration of TLR4-dependent upregulation of cytokines in an AD mouse model is demonstrated and suggests that TLR 4 signaling is involved in AD progression and thatTLR4 signaling can be a new therapeutic target for AD.
Journal ArticleDOI

TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease

TL;DR: The results indicate that TLR4 is not involved in the initiation of Aβ deposition and that, as Aβ deposits start, microglia are activated viaTLR4 signaling to reduce A β deposits and preserve cognitive functions from Aβ-mediated neurotoxicity.
Journal ArticleDOI

Exploratory activity and spatial learning in 12-month-old APP695SWE/co+PS1/ΔE9 mice with amyloid plaques

TL;DR: In the Morris water maze, APP(695)SWE/co+PS1/DeltaE9 mice were impaired during acquisition of the hidden platform sub-task and the probe trial but not in the visible platform test, indicating a selective spatial deficit and disinhibitory tendencies in a mouse model with amyloid pathology.
Journal ArticleDOI

Anti-Aβ single chain antibody delivery via adeno-associated virus for treatment of Alzheimer’s disease

TL;DR: A novel gene therapy modality where an adeno-associated virus (AAV) encoding anti-Aβ single-chain antibody (scFv) is injected into the corticohippocampal regions of AD mouse models may be a feasible solution for AD without eliciting inflammation.